Using antiangiogenic therapy to reduce bleeding in patients with hereditary hemorrhagic telangiectasia
Antiangiogenic Therapy to Reduce Bleeding and Improve Health-Related Quality of Life in Hereditary Hemorrhagic Telangiectasia
This study is looking at whether a medication called bevacizumab can help people with hereditary hemorrhagic telangiectasia (HHT) by reducing bleeding episodes and making their lives better.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10886041 on NIH RePORTER |
What this research studies
This research investigates the use of an anti-VEGF monoclonal antibody, bevacizumab, to treat hereditary hemorrhagic telangiectasia (HHT), a genetic bleeding disorder. The study aims to evaluate the effectiveness of this therapy in reducing severe bleeding episodes and improving the overall quality of life for affected individuals. By conducting a phase II clinical trial, the researchers will gather data on the impact of bevacizumab on bleeding frequency, hemoglobin levels, and patient-reported health outcomes. This approach builds on previous observational studies that showed promising results but lacked standardized methodologies.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with hereditary hemorrhagic telangiectasia who experience severe bleeding and are dependent on blood transfusions or iron infusions.
Not a fit: Patients who do not have hereditary hemorrhagic telangiectasia or those who are not experiencing significant bleeding issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that significantly reduces bleeding and improves the quality of life for patients with hereditary hemorrhagic telangiectasia.
How similar studies have performed: Previous observational studies have shown success with bevacizumab in reducing bleeding in HHT, indicating a promising avenue for further investigation.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Al-Samkari, Hanny T — Massachusetts General Hospital
- Study coordinator: Al-Samkari, Hanny T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.